Table III. Cox regression models of predictors of mortality in DLBCL patients.
| Factors | Univariate model | Multiple variable model | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Hazard Rate | 95% CI | Hazard Rate | 95% CI | |||
| Age, years | ||||||
| ≤60 | Reference | |||||
| >60 | 1.58* | 1.25 | 2.00 | 1.53* | 1.17 | 2.00 |
| Gender | ||||||
| Female | Reference | |||||
| Male | 1.07 | 0.85 | 1.35 | 1.23 | 0.97 | 1.57 |
| Race | ||||||
| White | Reference | |||||
| Black | 1.23 | 0.93 | 1.64 | 1.22 | 0.90 | 1.67 |
| Other | 0.81 | 0.38 | 1.73 | 1.07 | 0.49 | 2.32 |
| ECOG performance status | ||||||
| 0-1 | Reference | |||||
| ≥2 | 3.45* | 2.68 | 4.45 | 2.62* | 1.97 | 3.49 |
| LDH level | ||||||
| Normal | Reference | |||||
| >ULN | 2.13* | 1.56 | 2.91 | 1.59* | 1.15 | 2.21 |
| Disease stage | ||||||
| I/II | Reference | |||||
| III/IV | 1.51* | 1.19 | 1.93 | 1.20 | 0.91 | 1.59 |
| No. of extranodal sites | ||||||
| 0-1 | Reference | |||||
| ≥2 | 1.33 | 1.00 | 1.78 | 0.92 | 0.66 | 1.28 |
| B-symptoms | ||||||
| Absent | Reference | |||||
| Present | 1.49* | 1.15 | 1.92 | 1.20 | 0.92 | 1.58 |
| Insurance Type | ||||||
| Private +/- M/M | Reference | |||||
| Medicaid | 1.29 | 0.87 | 1.93 | 1.36 | 0.88 | 2.09 |
| Medicare +/- Medicaid | 1.41* | 1.01 | 1.96 | 0.95 | 0.66 | 1.36 |
| Uninsured | 0.45 | 0.14 | 1.40 | 0.51 | 0.16 | 1.64 |
| Employed | ||||||
| No | Reference | |||||
| Yes | 0.93 | 0.66 | 1.31 | 1.07 | 0.74 | 1.54 |
| Diagnosis Era | ||||||
| 1992-1997 | Reference | |||||
| 1998-2002 | 1.46* | 1.08 | 1.97 | 1.62* | 1.17 | 2.26 |
| 2003-2010 | 0.95 | 0.67 | 1.34 | 1.47 | 0.93 | 2.34 |
| 1981-1991 | 0.59 | 0.26 | 1.30 | 0.47 | 0.20 | 1.09 |
| First line of treatment | ||||||
| CHOP | Reference | |||||
| R-CHOP | 0.61* | 0.47 | 0.81 | 0.66* | 0.46 | 0.94 |
| R +/- Other | 1.21 | 0.78 | 1.89 | 1.09 | 0.65 | 1.82 |
| Other | 0.88 | 0.61 | 1.27 | 0.89 | 0.60 | 1.33 |
| Family Hist. of Lymphoma | ||||||
| Absent | Reference | |||||
| Present | 0.72 | 0.43 | 1.22 | 0.79 | 0.46 | 1.35 |
*
Indicates statistical significance
Abbreviations: CI, Confidence Interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal; M/M, Medicare/Medicaid; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).